[Pharmacokinetic aspects of tuberculosis therapy with a fixed combination of rifampicin, isoniazide and pyrazinamide]
- PMID: 1897286
[Pharmacokinetic aspects of tuberculosis therapy with a fixed combination of rifampicin, isoniazide and pyrazinamide]
Abstract
The here described investigations show correspondingly that the administration of isoniazid, rifampicin and pyrazinamide in a fixed combination of the administration of the individual substances is bioequivalent under pharmacokinetic aspects. Further investigations on large populations of patients must, however, still confirm whether or not the advantages of the fix combination striven for or theoretically to be expected can be proved in practice.
Similar articles
-
Comparative bioavailability of rifampicin, isoniazid and pyrazinamide from a four drug fixed dose combination with separate formulations at the same dose levels.Int J Pharm. 2004 May 19;276(1-2):41-9. doi: 10.1016/j.ijpharm.2004.02.019. Int J Pharm. 2004. PMID: 15113612 Clinical Trial.
-
Bioavailability of isoniazid, rifampicin and pyrazinamide (in free combination or fixed-triple formulation) in intermittent antituberculous chemotherapy.Monaldi Arch Chest Dis. 1993;48(3):205-9. Monaldi Arch Chest Dis. 1993. PMID: 8369784 Clinical Trial.
-
[Tisamide in the complex treatment of tuberculosis].Probl Tuberk. 1990;(7):43-5. Probl Tuberk. 1990. PMID: 2235951 Clinical Trial. Russian.
-
Whither short-course chemotherapy?Br J Dis Chest. 1981 Oct;75(4):331-57. doi: 10.1016/0007-0971(81)90022-x. Br J Dis Chest. 1981. PMID: 7030377 Review. No abstract available.
-
The near future: improving the activity of rifamycins and pyrazinamide.Tuberculosis (Edinb). 2010 May;90(3):177-81. doi: 10.1016/j.tube.2010.03.005. Epub 2010 Apr 9. Tuberculosis (Edinb). 2010. PMID: 20382083 Review.